Health Canada has approved the first generic version of Novo Nordisk's blockbuster diabetes drug Ozempic, a move expected to increase access and reduce costs for patients in Canada. The approval, announced on April 28, 2026, marks a significant milestone in the pharmaceutical landscape, as Ozempic has been widely prescribed for type 2 diabetes and has gained popularity for its weight loss effects.
What This Means for Patients
The generic version, produced by an unnamed manufacturer, will offer a more affordable alternative to the brand-name drug, which has been priced at around $300 per monthly injection without insurance. Health Canada stated that the generic meets the same safety and efficacy standards as the original. This development could lead to savings for both patients and the healthcare system.
Background on Ozempic
Ozempic, known generically as semaglutide, is a GLP-1 receptor agonist that helps control blood sugar levels and has been associated with significant weight loss. It has been on the Canadian market since 2018 and has seen soaring demand, leading to shortages in some regions. The approval of a generic is expected to alleviate supply pressures.
Novo Nordisk has not commented on the approval, but analysts predict the generic will capture a substantial market share. The move aligns with broader efforts by Health Canada to increase competition and reduce drug prices.
